193 related articles for article (PubMed ID: 34903710)
1. The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.
Karbon G; Haschka MD; Hackl H; Soratroi C; Rocamora-Reverte L; Parson W; Fiegl H; Villunger A
Cell Death Dis; 2021 Dec; 12(12):1151. PubMed ID: 34903710
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
3. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.
Abdel-Fatah TM; Perry C; Dickinson P; Ball G; Moseley P; Madhusudan S; Ellis IO; Chan SY
Ann Oncol; 2013 Nov; 24(11):2801-7. PubMed ID: 23908177
[TBL] [Abstract][Full Text] [Related]
4. The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest.
Haschka MD; Soratroi C; Kirschnek S; Häcker G; Hilbe R; Geley S; Villunger A; Fava LL
Nat Commun; 2015 Apr; 6():6891. PubMed ID: 25922916
[TBL] [Abstract][Full Text] [Related]
5. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
6. Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells.
Nakajima W; Miyazaki K; Asano Y; Kubota S; Tanaka N
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918002
[TBL] [Abstract][Full Text] [Related]
7. MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment.
Haschka MD; Karbon G; Soratroi C; O'Neill KL; Luo X; Villunger A
Cell Death Differ; 2020 Aug; 27(8):2297-2312. PubMed ID: 32015503
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
9. HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.
Sgubin M; Pegoraro S; Pellarin I; Ros G; Sgarra R; Piazza S; Baldassarre G; Belletti B; Manfioletti G
Cell Death Dis; 2022 May; 13(5):429. PubMed ID: 35504904
[TBL] [Abstract][Full Text] [Related]
10. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
11. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
12. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
14. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
15. Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.
Lucantoni F; Lindner AU; O'Donovan N; Düssmann H; Prehn JHM
Cell Death Dis; 2018 Jan; 9(2):42. PubMed ID: 29352235
[TBL] [Abstract][Full Text] [Related]
16. The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.
Hüsemann LC; Reese A; Radine C; Piekorz RP; Budach W; Sohn D; Jänicke RU
Cell Cycle; 2020 Feb; 19(4):464-478. PubMed ID: 31959066
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer - BCL2 in prognosis and prediction. Review.
Bouchalova K; Kharaishvili G; Bouchal J; Vrbkova J; Megova M; Hlobilkova A
Curr Drug Targets; 2014; 15(12):1166-75. PubMed ID: 25374001
[TBL] [Abstract][Full Text] [Related]
18. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
19. Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
Ploner C; Rainer J; Lobenwein S; Geley S; Kofler R
Apoptosis; 2009 Jun; 14(6):821-8. PubMed ID: 19421859
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
